PROTAC RIPK degrader-2

PROTAC RIPK degraders -2 is a non-peptide PROTAC based on von Hippel-Lindau and targets serine-threonine kinase RIPK2, which is highly selective to the degradation of RIPK2. PROTAC RIPK degrader-2 acts as an activator to increase cell death and activate ion channels in cancer cells. PROTAC RIPK degrader-2 also can inhibit protein interactions, such as receptors and ligands, involved in a variety of diseases, such as cancer and diabetes[1][2].

Product Specifications

CAS Number

[1801547-16-9]

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

PROTACs; RIP kinase

Type

Reference compound

Related Pathways

Apoptosis; PROTAC

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/protac-ripk-degrader-2.html

Purity

99.89

Solubility

DMSO : 150 mg/mL (ultrasonic)

Smiles

CC1=C(SC=N1)C2=CC=C(CNC([C@H]3N(C([C@H](C(C)(C)C)NC(COCCOCCOCCOCCOC4=CC5=C(C(NC6=CC=C(SC=N7)C7=C6)=CC=N5)C=C4S(C(C)(C)C)(=O)=O)=O)=O)C[C@H](O)C3)=O)C=C2

Molecular Formula

C52H65N7O11S3

Molecular Weight

1060.31

Precautions

H315, H319, H320

References & Citations

[1]Bondeson DP, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015 Aug;11 (8) :611-7.|[2]Wang C, et al. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. Eur J Med Chem. 2022 Jan 5;227:113906.